King Luther Capital Management Corp Purchases 169,900 Shares of Phreesia, Inc. $PHR

King Luther Capital Management Corp increased its position in Phreesia, Inc. (NYSE:PHR) by 172.6% during the fourth quarter, Holdings Channel reports. The firm owned 268,314 shares of the company’s stock after buying an additional 169,900 shares during the quarter. King Luther Capital Management Corp’s holdings in Phreesia were worth $4,540,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of PHR. Royal Bank of Canada raised its holdings in shares of Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after purchasing an additional 16,309 shares during the period. AQR Capital Management LLC increased its holdings in shares of Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after acquiring an additional 2,158 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after acquiring an additional 11,181 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after acquiring an additional 2,402 shares during the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Trading Up 3.5%

Shares of NYSE:PHR opened at $9.45 on Friday. Phreesia, Inc. has a 1 year low of $7.77 and a 1 year high of $32.76. The business’s 50 day simple moving average is $9.49 and its 200 day simple moving average is $13.60. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.53. The company has a market capitalization of $583.79 million, a P/E ratio of 63.01 and a beta of 0.89.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Wednesday, May 27th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03. Phreesia had a net margin of 1.85% and a return on equity of 5.30%. The business had revenue of $130.94 million during the quarter, compared to analysts’ expectations of $130.08 million. During the same quarter in the prior year, the business posted ($0.07) earnings per share. Phreesia’s revenue was up 12.9% compared to the same quarter last year. On average, research analysts anticipate that Phreesia, Inc. will post 0.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 14,483 shares of Phreesia stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $116,877.81. Following the transaction, the general counsel owned 163,485 shares in the company, valued at $1,319,323.95. The trade was a 8.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Balaji Gandhi sold 3,829 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total transaction of $43,114.54. Following the completion of the sale, the chief financial officer owned 146,740 shares in the company, valued at $1,652,292.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 50,493 shares of company stock worth $461,983. Insiders own 5.20% of the company’s stock.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Phreesia reported first-quarter fiscal 2027 results that beat expectations, with EPS of $0.05 versus $0.02 expected and revenue of $130.94 million topping estimates. Management also pointed to 12.9% year-over-year revenue growth and said it is entering fiscal 2027 with strong momentum and several growth initiatives. Phreesia Announces First Quarter Fiscal 2027 Results
• Positive Sentiment: DA Davidson reiterated a Buy rating and set a $14 price target, suggesting meaningful upside from current levels. Piper Sandler also has a higher target than the recent trading price, even though it lowered its stance to neutral. DA Davidson Reiterates Buy Rating on Phreesia Inc. (PHR)
• Neutral Sentiment: Analysts and market commentary highlighted that the company’s outlook remains tied to continued execution in its Network Solutions segment and broader healthcare platform, making the earnings beat important for confirming the growth story. Phreesia Inc (PHR) Q1 2027 Earnings Call Highlights
• Negative Sentiment: Multiple law firms issued fresh class-action reminders and deadline notices related to allegations that Phreesia made misleading statements about growth prospects, especially in its Network Solutions segment. This keeps litigation risk in focus and can weigh on sentiment. Lost Money on Phreesia, Inc. (PHR)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: Piper Sandler downgraded Phreesia from overweight to neutral, signaling a more cautious view even as it maintained a $12 price target. Piper Sandler Downgrades Phreesia from Overweight to Neutral

Analysts Set New Price Targets

A number of research firms recently weighed in on PHR. Citigroup boosted their target price on Phreesia from $10.00 to $12.00 and gave the stock a “neutral” rating in a report on Thursday. Citizens Jmp reaffirmed a “market perform” rating on shares of Phreesia in a report on Wednesday, April 1st. Stephens reduced their target price on shares of Phreesia from $32.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 31st. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $16.00 target price (down from $24.00) on shares of Phreesia in a report on Tuesday, March 31st. Finally, BMO Capital Markets reduced their target price on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. Nine equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Phreesia currently has a consensus rating of “Hold” and a consensus target price of $16.65.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.